These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 16360673)

  • 21. Brain-derived neurotrophic factor in schizophrenia and its relation with dopamine.
    Guillin O; Demily C; Thibaut F
    Int Rev Neurobiol; 2007; 78():377-95. PubMed ID: 17349867
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Elevated clozapine serum level after treatment with amiodarone.
    Stevens JR; Freudenreich O; Stern TA
    Psychosomatics; 2008; 49(3):255-7. PubMed ID: 18448783
    [No Abstract]   [Full Text] [Related]  

  • 23. Neuregulin 1 (8p12) and childhood-onset schizophrenia: susceptibility haplotypes for diagnosis and brain developmental trajectories.
    Addington AM; Gornick MC; Shaw P; Seal J; Gogtay N; Greenstein D; Clasen L; Coffey M; Gochman P; Long R; Rapoport JL
    Mol Psychiatry; 2007 Feb; 12(2):195-205. PubMed ID: 17033632
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Difficulties in the medical treatment of prolactinoma in a patient with schizophrenia--a case report with a review of the literature.
    Konopelska S; Quinkler M; Strasburger CJ; Ventz M
    J Clin Psychopharmacol; 2008 Feb; 28(1):120-2. PubMed ID: 18204364
    [No Abstract]   [Full Text] [Related]  

  • 25. [Subjective aspects of pharmacotherapy in schizophrenia during implementation of chlorpromazine in Poland--a review].
    Murawiec S
    Psychiatr Pol; 2003; 37(4):657-67. PubMed ID: 14560494
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The complexity of the dopaminergic synapses and their modulation by antipsychotics.
    Leuner K; Müller WE
    Pharmacopsychiatry; 2006 Feb; 39 Suppl 1():S15-20. PubMed ID: 16508891
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Gene polymorphism and gene expression in schizophrenia].
    Mátyás T
    Psychiatr Hung; 2006; 21(6):404-12. PubMed ID: 17438657
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Schizophrenia: diverse approaches to a complex disease.
    Sawa A; Snyder SH
    Science; 2002 Apr; 296(5568):692-5. PubMed ID: 11976442
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Psychopharmacological implications of dopamine and dopamine antagonists: a critical evaluation of current evidence.
    Hornykiewicz O
    Neuroscience; 1978; 3(9):773-83. PubMed ID: 30919
    [No Abstract]   [Full Text] [Related]  

  • 30. Update on key previously proposed candidate genes for schizophrenia.
    Schwab SG; Wildenauer DB
    Curr Opin Psychiatry; 2009 Mar; 22(2):147-53. PubMed ID: 19553868
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antipsychotic pathway genes with expression altered in opposite direction by antipsychotics and amphetamine.
    Ko F; Tallerico T; Seeman P
    Synapse; 2006 Aug; 60(2):141-51. PubMed ID: 16715494
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Classics in Chemical Neuroscience: Chlorpromazine.
    Boyd-Kimball D; Gonczy K; Lewis B; Mason T; Siliko N; Wolfe J
    ACS Chem Neurosci; 2019 Jan; 10(1):79-88. PubMed ID: 29929365
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dopamine and its relation to schizophrenia and antipsychotic drugs.
    Tarnoff GM
    Bull Menninger Clin; 1978 Jul; 42(4):321-38. PubMed ID: 29683
    [No Abstract]   [Full Text] [Related]  

  • 34. Glutamate and schizophrenia: phencyclidine, N-methyl-D-aspartate receptors, and dopamine-glutamate interactions.
    Javitt DC
    Int Rev Neurobiol; 2007; 78():69-108. PubMed ID: 17349858
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The serotonin transporter and clozapine response.
    Arranz MJ; Bolonna AA; Munro J; Curtis CJ; Collier DA; Kerwin RW
    Mol Psychiatry; 2000 Mar; 5(2):124-5. PubMed ID: 10822334
    [No Abstract]   [Full Text] [Related]  

  • 36. Improving Current Treatments for Schizophrenia.
    Maric NP; Jovicic MJ; Mihaljevic M; Miljevic C
    Drug Dev Res; 2016 Nov; 77(7):357-367. PubMed ID: 27633376
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Developmental disruptions in neural connectivity in the pathophysiology of schizophrenia.
    Karlsgodt KH; Sun D; Jimenez AM; Lutkenhoff ES; Willhite R; van Erp TG; Cannon TD
    Dev Psychopathol; 2008; 20(4):1297-327. PubMed ID: 18838043
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Neuropharmacology of second-generation antipsychotic drugs: a validity of the serotonin-dopamine hypothesis.
    Kuroki T; Nagao N; Nakahara T
    Prog Brain Res; 2008; 172():199-212. PubMed ID: 18772034
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacologic implications of neurobiological models of schizophrenia.
    Goff DC
    Harv Rev Psychiatry; 2005; 13(6):352-9. PubMed ID: 16373329
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Differential RNA expression between schizophrenic patients and controls of the dystrobrevin binding protein 1 and neuregulin 1 genes in immortalized lymphocytes.
    Chagnon YC; Roy MA; Bureau A; Mérette C; Maziade M
    Schizophr Res; 2008 Mar; 100(1-3):281-90. PubMed ID: 18234478
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.